RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the publication of groundbreaking Phase 2 trial results ...

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced 24-hour systolic blood pressure in individuals with uncontrolled and treatment-resistant hypertension, according to ...

The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

Hypertension (HTN) increases the risk of development of HF and it precedes it in 75% of cases. HF patients are nearly evenly divided between those with reduced left ventricular (LV) function or ...

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced systolic blood pressure in patients with ...

A discussion of a challenging case of renal artery denervation for resistant hypertension. Hypertension (HTN) is estimated to ...

Lorundrostat reduced blood pressure (BP) in people with confirmed uncontrolled and treatment-resistant hypertension, ...

THURSDAY, April 17, 2025 (HealthDay News) — Early pregnancy blood pressure (BP) trajectories are associated with new-onset hypertension up to 14 years later, according to a study published online ...

Lorundrostat effectively reduced 24-hour blood pressure in patients with well-treated, uncontrolled hypertension in the phase ...

Mineralys Therapeutics, Inc. has announced the publication of detailed results from its pivotal Phase 2 Advance-HTN trial in the New England Journal of Medicine. The study assessed lorundrostat ...

Mineralys Therapeutics (MLYS) announced that the New England Journal of Medicine, or NEJM, published results from the company’s pivotal Phase 2 ...

Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dy ...